Table 3 –
Characteristics of participants by cohort
| Characteristic | Cohort 1 (N = 501; 50%) | Cohort 2 (N = 499; 50%) | p value * |
|---|---|---|---|
| Age | 64 (62, 66) | 69 (67, 71) | <0.0001 |
| Family history, n (%) | 26 (5.2) | 27 (5.4) | 0.9 |
| Prior negative biopsy, n (%) | 128 (26) | 153 (31) | 0.079 |
| Total PSA at diagnosis (ng/ml; N = 992) | 4.5 (3.5, 5.5) | 6.5 (5.5, 7.5) | <0.0001 |
| Clinical T stage, n (%) | |||
| T1a/b/c | 273 (54) | 266 (53) | 0.7 |
| T2a | 72 (14) | 78 (16) | |
| T2b | 42 (8.4) | 33 (6.6) | |
| T2c | 21 (4.2) | 28 (5.6) | |
| T3/4 | 19 (3.8) | 16 (3.2) | |
| Missing, n (%) | 74 (15) | 78 (16) | |
| Gleason grade group, n (%) | |||
| 1 | 85 (17) | 99 (20) | 0.5 |
| 2 | 180 (36) | 187 (37) | |
| 3 | 142 (28) | 129 (26) | |
| 4–5 | 94 (19) | 84 (17) | |
| Education, n (%) | |||
| Less than high school | 96 (19) | 109 (22) | 0.8 |
| High school | 147 (29) | 147 (29) | |
| College | 155 (31) | 153 (31) | |
| Postgraduate | 74 (15) | 70 (14) | |
| Missing | 29 (5.8) | 20 (4.0) |
PSA = prostate-specific antigen.
Estimates were given as median (quartile 1, quartile 3) or frequency (percentage).
*
p values were calculated using Wilcoxon rank-sum test for continuous and Fisher’s exact test for categorical variables.